Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study

Peter A. Fasching a,*, J. Thaddeus Beck b, Arlene Chan c, Michele De Laurentiis d, Francisco J. Esteva e, Guy Jerusalem f, Patrick Neven g, Xavier Pivot h, Giulia V. Bianchi i, Miguel Martin j, David Chandiwana k, Brad Lanoue k, Antonia Ridolfi l, Yingbo Wang m, Karen Rodriguez Lorenc n, Arnd Nusch n

a University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Department of Gynecology and Obstetrics, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
b Highlands Oncology Group, Fayetteville, AR, USA
c Breast Cancer Research Centre-Western Australia, Nedlands, WA, Australia
d Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Naples, Italy
e NYU Langone Health, New York, NY, USA
f CHU de Liège, University of Liège, Liège, Belgium
g Multidisciplinary Breast Centre, Universitätsklinikum Eppendorf, Hamburg, Germany
h Institut Régional Du Cancer, Strasbourg, France
i Fondazione IRCCS - Istituto Nazionale Dei Tumori, Milan, Italy
j Instituto de Investigación Sanitaria Gregorio Marañón, Ciberonc Geicam, Universidad Complutense de Madrid, Madrid, Spain
k Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
l Novartis Pharma SAS, Rueil-Malmaison, France
m Novartis Pharma AG, Basel, Switzerland
n Practice for Haematology and Internal Oncology, Velbert, Germany

A R T I C L E   I N F O

Article history:
Received 28 July 2020
Received in revised form 17 September 2020
Accepted 18 September 2020
Available online 23 September 2020

Keywords:
Breast cancer
Metastatic
Patient-reported outcomes
Quality of life

A B S T R A C T

Purpose: In the MONALEESA-3 Phase III trial of patients with hormone receptor–positive human epidermal growth factor receptor–negative advanced breast cancer, ribociclib plus fulvestrant significantly improved progression-free survival (PFS) and overall survival (OS). Here, we present patient-reported outcomes from the trial, including health-related quality of life (HRQOL).

Methods: Patients were randomized (2:1) to receive ribociclib plus fulvestrant or placebo plus fulvestrant. Time to definitive 10% deterioration (TTD) from baseline in HRQOL (global health status [GHS] from the EORTC QLQ-C30 questionnaire) and pain (BPI-SF questionnaire) were assessed using Kaplan-Meier estimates; a stratified Cox regression model was used to estimate the hazard ratio (HR) and 95% CIs.

Results: Deterioration >10% in the EORTC-QLQ-C30 GHS was observed in 33% of patients in the ribociclib group vs 34% of patients in the placebo (reference) group (HR for TTD >10% = 0.81 [95% CI, 0.62–1.1]). Similar findings were noted for TTD >5% (HR = 0.79 [95% CI, 0.61–1.0]) and TTD >15% (HR = 0.81 [95% CI, 0.60–1.08]). TTD >10% in emotional functioning (HR = 0.76 [95% CI, 0.57–1.01]) trended in favor of the ribociclib group, whereas results for fatigue and pain were similar between arms. TTD >10% in BPI-SF pain severity index score (HR = 0.77 [95% CI, 0.57–1.05]) and worst pain item score (HR = 0.81 [95% CI, 0.58–1.12]) trended in favor of ribociclib vs placebo.

Conclusions: In addition to significantly prolonging PFS and OS compared with placebo plus fulvestrant, adding ribociclib to fulvestrant maintains HRQOL.

© 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Patients with breast cancer receiving early-line therapy typically report a relatively high health-related quality of life (HRQOL) that
may deteriorate over time as the disease progresses [1–3]. Adding novel therapies to existing treatments can delay disease progression but can also result in additional toxicities, which may have an impact on HRQOL [4]. Consequently, advanced breast cancer is associated with reduced HRQOL scores, including role functioning, pain, and breast cancer-related symptoms [5]. Recent real-world evidence demonstrated that disease progression negatively affects the QOL of patients with metastatic breast cancer; therefore, maintaining QOL while improving progression-free survival (PFS) outcomes is a desirable goal in the clinical management of this disease [2,6]. The European Society for Medical Oncology guidelines recommend that the effect of new treatments on HRQOL be assessed in addition to impact on efficacy and safety [7]. In recent trials, patient-reported outcomes (PROs) have emerged as crucial tools for the benefit-risk assessment of novel regimens [3,8–12].

Ribociclib, an oral CDK4/6 inhibitor, in combination with an aromatase inhibitor or fulvestrant is recommended by current guidelines across many countries as a treatment option in pre/perimenopausal and postmenopausal women with hormone receptor–positive (HR+/HER2−)/human epidermal growth factor receptor–negative (HER2−) advanced breast cancer [7,13]. To date, all 3 randomized clinical trials (MONALEESA-2, MONALEESA-3, and MONALEESA-7) investigating combinations of ribociclib with endocrine therapy in patients with HR+/HER2− advanced breast cancer have shown a significantly longer PFS with ribociclib therapy vs placebo [14–16]. The MONALEESA-7 Phase III trial was the first study in which the addition of ribociclib to endocrine therapy demonstrated a statistically significant overall survival (OS) benefit compared with placebo (hazard ratio [HR] = 0.71 [95% CI, 0.54–0.95]; P = .00973) in premenopausal women with advanced breast cancer [17].

MONALEESA-3 is a Phase III trial of first- or second-line ribociclib plus fulvestrant vs placebo in premenopausal HR+/HER2− patients with advanced breast cancer [16]. With a median follow-up of 20.4 months, ribociclib treatment demonstrated longer PFS vs placebo (median, 20.5 vs 12.8 months; HR = 0.593 [95% CI, 0.480–0.732]; P < .001) and a manageable safety profile, in line with previously published ribociclib studies. The PFS benefit was consistent across prespecified subgroups. Ribociclib plus fulvestrant reduced the risk of progression or death by 42% as first-line therapy (HR = 0.577 [95% CI, 0.415–0.802]) and by 44% as second-line or early-relapse therapy (HR = 0.565 [95% CI, 0.428–0.744]). OS was significantly improved with ribociclib treatment than with placebo (HR = 0.72 [95% CI, 0.57–0.92]; P < .01129) [18].

A growing body of evidence indicates that pain management may be associated with improved QOL [19]. This analysis evaluates PROs, including HRQOL and pain scores, in patients enrolled in the MONALEESA-3 trial.

### 2. Patients and methods

#### 2.1. Study design and participants

MONALEESA-3 (NCT02422615) is a Phase III, randomized, double-blind, placebo-controlled trial evaluating ribociclib plus fulvestrant in patients with HR+/HER2− advanced breast cancer who are receiving treatment in the first- or second-line/early-relapse settings. Patients were randomized 2:1 to receive either ribociclib (600 mg/day; 3 weeks on/1 week off) or placebo in combination with fulvestrant (500 mg on day 1 of each 28-day cycle, with an additional dose on day 15 of cycle 1). Details of participants, study treatments, and procedures have been reported previously [16]. PROs were a secondary objective. The study was initiated in June 2015, and the data cutoff for this analysis was June 3, 2019. The study was performed in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. The study protocol was approved by an independent ethics committee and/or local institutional review boards for each study site. A steering committee comprising participating international investigators and Novartis representatives oversaw the study conduct. An independent data monitoring committee assessed the safety data. All patients provided written informed consent.

#### 2.2. PRO assessments

PROs were analyzed using the European Organisation for Research and Treatment of Cancer (EORTC) quality-of-life questionnaire (QLQ)-C30 V3.0 along with the Brief Pain Inventory-Short form (BPI-SF) questionnaire and the EuroQol 5-level instrument (EQ-5D-5L, Version 4.0) to evaluate HRQOL, functioning, treatment-related side effects, global health status, and disease symptoms, such as cancer-related pain. Patients were asked to complete the questionnaires at screening; every 8 weeks for the first 18 months, and then every 12 weeks until disease progression, death, withdrawal of consent, loss to follow-up, or patient/guardian decision; and at the end of treatment. No post-progression PRO assessments were performed.

Questionnaire responses were scored using a scale ranging from 0 to 100 for QLC-C30 and from 0 to 10 for BPI-SF. For functional and global health status/QOL scales, a higher numerical score represents a better level of functioning/HQQL health states. For symptomatic scales, a higher numerical score represents greater symptom severity/higher pain intensity.

The primary variable of interest was global health status/global QOL score of the EORTC QLC-C30. Secondary variables of interest included EORTC QLC-C30 physical, emotional, and social functioning subscale scores and BPI-SF worst pain item, pain severity index, and pain interference indices.

#### Table 1

| Score, Mean (SD) | Global HRQOL | Symptom Scores |
|-----------------|--------------|----------------|
|                 | Fatigue      | Diarrhea       | Nausea/Vomiting | Pain |
| **Ribociclib + fulvestrant** | | | | |
| Baseline (n = 447) | 65.5 (19.1) | 32.2 (23.1) | 6.4 (15.7) | 6.4 (14.0) | 30.9 (25.5) |
| Cycle 3 day 1 (n = 362) | 69.9 (19.6) | 33.1 (23.5) | 6.7 (15.7) | 8.9 (15.4) | 25.1 (24.2) |
| Cycle 15 day 1 (n = 219) | 71.0 (18.5) | 32.3 (22.6) | 6.7 (17.4) | 6.7 (12.3) | 25.3 (23.3) |
| **Placebo + fulvestrant** | | | | |
| Baseline (n = 224) | 68.4 (18.5) | 30.5 (21.4) | 6.7 (15.4) | 7.0 (14.7) | 27.8 (25.9) |
| Cycle 3 day 1 (n = 169) | 70.9 (17.5) | 29.1 (21.5) | 6.7 (14.4) | 4.2 (9.8) | 24.1 (23.4) |
| Cycle 15 day 1 (n = 96) | 73.5 (16.6) | 26.2 (18.9) | 6.0 (14.4) | 5.2 (11.7) | 23.1 (21.5) |
| **EORTC reference value n = 1147** [20] | | | | |
| 60.2 (25.5) | 36.3 (27.0) | 5.8 (15.2) | 10.3 (19.7) | 30.9 (25.6) |

EORTC-QLQ-C30 European Organisation for Research and Treatment of Cancer core quality-of-life questionnaire. HRQOL health-related quality of life.
2.3. Statistical analyses

Changes from baseline in all subscales obtained from EORTC QLQ-C30 were estimated using a linear mixed model that included treatment, stratification factors, baseline score, visit time, and treatment by visit time interactions as fixed effects and patient as a random effect in the model. Additionally, change from baseline in the domain scores, health states, overall health status, and index values at the time of each assessment were summarized. Descriptive statistics were used to summarize the changes in EORTC QLQ-C30 pain scores.

Time to definitive deterioration ≥10% (TTD; defined as ≥10% worsening of the scales score relative to baseline, with no later improvement above this threshold observed during the treatment period, or death due to any cause) in the global health status/QOL score was investigated. In addition, TTDs of 5% and 15% were assessed and presented. The survival distributions were presented throughout the study treatment, global health status/QOL scores at baseline were well balanced between treatment groups: 65.5 (±19.1) in the ribociclib group and 68.4 (±18.5) in the placebo group (Table 1) and were in line with the EORTC QLQ-C30 reference values expected for recurrent/metastatic breast cancer [20] and those reported for a general population (ie, not cancer specific) of women aged 60–69 years in North American and Europe (mean, 65.6 years) [21].

The mean (SD) EORTC QLQ-C30 symptom scores assessed at baseline included fatigue (32.2 [±23.1] in the ribociclib group vs 30.5 [±21.4] in the placebo group), diarrhea (6.4 [±15.7] vs 6.7 [±14.5]), nausea and vomiting (6.4 [±14.0] vs 7.0 [±14.7]), and pain (30.0 [±25.5] vs 27.8 [±25.9]), which were all similar to the EORTC QLQ-C30 reference values (Table 1) [20]. In general, at 8 weeks (day 1 of cycle 3) and later during treatment, the EORTC QLQ-C30 symptom scores were maintained or improved slightly, irrespective of treatment.

Throughout the study treatment, global health status/QOL scores were improved from baseline and generally similar between treatment groups (Table 1 and Fig. 1). In both groups, this improvement from baseline was consistently maintained until end of treatment, after which it declined.

3. Results

3.1. Patient characteristics

Between June 2015 and June 2016, 726 patients were randomized at a 2:1 ratio to ribociclib plus fulvestrant (n = 484) or placebo plus fulvestrant (n = 242). Baseline demographics and disease characteristics have been published previously (Supplemental Table 1) [16].

Overall compliance rates of patients completing the EORTC QLQ-C30 questionnaire during the treatment period were high in both groups, with compliance rates at baseline of 92.1% in the ribociclib group and 93.4% in the placebo group. Compliance rates were >90% at the first postbaseline assessment and throughout the first year of treatment, respectively.

3.2. EORTC QLQ-C30 global health status/QOL score and symptom scales

The mean (standard deviation; SD) EORTC QLQ-C30 global health/QOL scores at baseline were well balanced between treatment groups: 65.5 (±19.1) in the ribociclib group and 68.4 (±18.5) in the placebo group (Table 1) and were in line with the EORTC QLQ-C30 reference values expected for recurrent/metastatic breast cancer [20] and those reported for a general population (ie, not cancer specific) of women aged 60–69 years in North American and Europe (mean, 65.6 years) [21].

The mean (SD) EORTC QLQ-C30 symptom scores assessed at baseline included fatigue (32.2 [±23.1] in the ribociclib group vs 30.5 [±21.4] in the placebo group), diarrhea (6.4 [±15.7] vs 6.7 [±14.5]), nausea and vomiting (6.4 [±14.0] vs 7.0 [±14.7]), and pain (30.0 [±25.5] vs 27.8 [±25.9]), which were all similar to the EORTC QLQ-C30 reference values (Table 1) [20]. In general, at 8 weeks (day 1 of cycle 3) and later during treatment, the EORTC QLQ-C30 symptom scores were maintained or improved slightly, irrespective of treatment.

Throughout the study treatment, global health status/QOL scores were improved from baseline and generally similar between treatment groups (Table 1 and Fig. 1). In both groups, this improvement from baseline was consistently maintained until end of treatment, after which it declined.

3.3. Time to definitive deterioration

Deterioration ≥10% in global HRQOL was observed in 159/484 patients in the ribociclib group vs 83/242 patients in the placebo group (Fig. 2a). This resulted in a numerical trend in favor of ribociclib in TTD ≥10% in global HRQOL (HR = 0.81 [95% CI, 0.62–1.1]). Similar findings were noted for TTD ≥5% (HR = 0.79 [95% CI, 0.61–1.0]; Fig. 2b) and TTD ≥15% (HR = 0.81 [95% CI, 0.60–1.0]; Fig. 2c). A delay in TTD ≥10% in global HRQOL was observed for patients who did not experience a PFS event compared with those who experienced a PFS event in the ribociclib group (Supplemental Fig 1a), the placebo group (Supplemental Fig 1b), and for patients across both treatment groups (Supplemental Fig 1c).

TTD ≥10% in EORTC QLQ-C30 functioning scores trended in favor of ribociclib. Mean TTD ≥10% with ribociclib vs placebo was 38.7 months (137 events) vs 34.9 months (69 events; HR = 0.82 [95% CI, 0.61–1.10]), respectively, for the physical functioning score; 38.6 months (137 events) vs 30.4 months (73 events; HR = 0.76 [95% CI, 0.57–1.01]), respectively, for the emotional functioning
Fig. 2. Time to definitive deterioration of global health status/QOL scale score of EORTC QLQ-C3 from baseline by ≥10% (a), ≥5% (b), and ≥15% (c). EORTC-QLQ-C30 European Organisation for Research and Treatment of Cancer core quality-of-life questionnaire, FUL fulvestrant, PBO placebo, QOL quality of life, RIB ribociclib.
score; and 39.6 months (129 events) vs 38.8 months (53 events; HR = 1.03 [95% CI, 0.75–1.42]), respectively, for the social functioning score.

TTD ≥10% in EORTC QLQ-C30 fatigue score was similar between treatment groups: median, 38.7 months with ribociclib vs 36.0 months with placebo (HR = 0.91 [95% CI, 0.68–1.22]; Fig. 3). TTD ≥10% in EORTC QLQ-C30 pain score was also similar between treatment groups; median, 41.9 months with ribociclib vs not estimable with placebo (HR = 1.06 [95% CI, 0.74–1.52]; Fig. 4). There were few patients in this trial with a deterioration ≥10% in diarrhea or nausea/vomiting, and median values were not reached for either domain in either treatment arm (data not shown).

3.4. Pain scores

At 8 weeks, the least squares mean change from baseline in EORTC QLQ-C30 pain scores was −4.0 in the ribociclib group (n = 362) vs −3.6 in the placebo group (n = 169), with a treatment difference of −0.3 (95% CI, −4.0 to 3.3). Through study treatment, pain scores were generally maintained until end of treatment (Supplemental Fig 2).

PROs based on the BPI-SF questionnaire indicated a trend in favor of ribociclib in TTD ≥10% in pain severity index score (HR = 0.77 [95% CI, 0.57–1.05]; Fig. 5). TTD ≥10% in BPI-SF worst pain item score (HR = 0.81 [95% CI, 0.58–1.12]) also favored ribociclib over placebo.

4. Discussion

This analysis of PROs in the MONALEESA-3 trial demonstrates that QOL was maintained until the end of treatment, and the previously demonstrated improvement in efficacy of ribociclib plus fulvestrant seemed to be accompanied by a lower risk for HRQOL deterioration compared with fulvestrant monotherapy, although the differences were not statistically significant. The EORTC QLQ-C30 global health/QOL score was improved from baseline and maintained during treatment but worsened when treatment was stopped in both treatment groups. Deterioration of HRQOL has been shown to coincide with disease progression [3]. The prolonged PFS reported in the ribociclib group (median, 20.5 months...
vs 12.8 months [16]) may have translated into the numerically longer median TTD ≥ 10% in global health score observed in this analysis.

Because of the established difficulty in interpreting longitudinal changes in individual symptom and functional subscales in HRQOL studies, only simple descriptive statistics were reported for changes from baseline in the PROs in this report. Comprehensive guidelines on the interpretation of EORTC QLC-C30 scores note that expected improvements over time are generally smaller than expected declines [22]. In this study, baseline EORTC QLQ-C30 global health/QOL and symptom subscale values were generally comparable to those in the general population across >10 countries worldwide and, most notably, with mean scores reported in women aged >60 years [21]. Therefore, an improvement in QOL during treatment would not be expected, and delaying deterioration in HRQOL in this trial, which was achieved with ribociclib treatment, should be considered an important result.

In addition to global health, the more specific EORTC QLC-C30 symptom scores, including fatigue, diarrhea, nausea and vomiting, and pain, were maintained or slightly improved from baseline throughout treatment. It is important to note that patients in both groups reported a reduction in pain score in early as close as 8 weeks, which was maintained throughout treatment; this result is in line with the MONALEESA-2 and MONALEESA-7 studies of ribociclib-based combinations [23,24]. The ribociclib group also demonstrated a trend toward a longer time to deterioration of global HRQOL, which may be a result of having a longer PFS than patients in the placebo group. Furthermore, assessment of TTD of pain scores of the BPI-SF questionnaire, a particularly important QOL instrument, supported the positive trend observed in the ribociclib group. Altogether, these findings suggest that ribociclib treatment does not worsen specific EORTC QLC-C30 symptoms and that the longer duration of PFS with ribociclib may result in a delay in deterioration of HRQOL in patients with HR+/HER2− advanced breast cancer.

In conclusion, these PRO findings indicate that overall HRQOL was maintained in postmenopausal HR+/HER2− patients with advanced breast cancer who received ribociclib plus fulvestrant as first- or second-line therapy. These results also reaffirm that, in MONALEESA-3, ribociclib prolonged PFS and OS while maintaining QOL. Generalizing to the entire MONALEESA trial program, these PROs from the MONALEESA-3 trial add to the growing body of evidence indicating that ribociclib in combination with endocrine therapy may maintain QOL while, at the same time, prolonging survival outcomes in patients with HR+/HER2− advanced breast cancer, irrespective of their menopausal status.

Declaration of competing interest

Dr. Fasching has received grants from Novartis, grants from Biontech, personal fees from Novartis, Roche, Pfizer, Celgene, Daichi-Sankyo, TEVA, AstraZeneca, Merck Sharp & Dohme, Myelo Therapeutics, Macrogenics, Eisai, Puma, grants from Cepheid, outside the submitted work; Dr. Chan has nothing to disclose; Dr. Beck has received grants for his institution from Novartis, outside the submitted work; Dr. De Laurentiis has received personal fees from Pfizer, Novartis, Roche, Celgene, Astra Zeneca, Eisai, Eli Lilly, Amgen, MSD, outside the submitted work; Dr. Esteva has received grants and personal fees from Novartis, Pfizer, Genentech/Roche, personal fees from Celltrion Healthcare, Seattle Genetics, grants from GlaxoSmithKline, outside the submitted work; Dr. Jerusalem has received personal fees from Novartis; grants, personal fees and non-financial support from Novartis, Roche, Pfizer, personal fees and non-financial support from Lilly, Amgen, BMS, Astra-Zeneca, personal fees from Celgene, Puma Technology, Daichi Sankyo, AbbVie, outside the submitted work; Dr. Neven has nothing to disclose; Dr. Pivot has nothing to disclose; Dr. Bianchi has received personal fees from Novartis, Eli Lilly, outside the submitted work; Dr. Martin has received personal fees from Lilly, Pfizer, AstraZeneca, GlaxoSmithKline, Pharmamar, Taiho Oncology, grants and personal fees from Novartis, Roche-Geneumegentech, outside the submitted work; Dr. Chandiwana reports other from Novartis, during the conduct of the study; Dr. Lanoue reports other from Novartis, during the conduct of the study; Dr. Ridolfi reports other from Novartis, during the conduct of the study; Dr. Wang has received personal fees and other from Novartis, outside the submitted work; Dr. Rodriguez Lorenc has received personal fees and other from Novartis, outside the submitted work; Dr. Nusch reports other from Novartis and Amgen, outside the submitted work.

Acknowledgments

The authors thank the patients who participated in the study and their families. Medical writing assistance was provided by Mihaela Marina, PhD, of MediTech Media, Ltd., funded by Novartis Pharmaceutical Company.
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://doi.org/10.1016/j.breast.2020.09.008.

Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

Informed consent
Informed consent was obtained from all individual participants included in the study.

Funding
This study was funded by Novartis Pharmaceutical Company.

References
[1] de Ligt KM, Heins M, Verloop J, Ezzendam NPM, Smorenburg CH, Koeveaar JC, Siesling S. The impact of health symptoms on health-related quality of life in early-stage breast cancer survivors. Breast Cancer Res Treat 2019;178(3):703–11. https://doi.org/10.1007/s10549-019-05433-3.
[2] Muller V, Nabieva N, Haberle L, Taran FA, Hartkopf AD, Volz B, Overkamp F, Brandl AL, Kolberg HC, Hadji P, Tesch H, Ettl J, Lux MP, Luftner D, Belleville E, Fasching PA, Janni W, Beck JT, Nabhack M, Wimmberger P, Hirscher C, Fehn TN, Bruker SY, Wallwiener D, Schneeweiss A, Wallwiener M. Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAE GNAT breast cancer registry. Breast 2018;173:154–60. https://doi.org/10.1016/j.breast.2017.08.009.
[3] Russo HS, Dieras V, Gelmon K, Finn RS, Slamon DJ, Martin M, Neven P, Shparyk Y, Moris A, Lu DR, Bhattacharyya H, Bartlett CH, Iyer S, Johnson K, Ettl J, Harbeck N. Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial. Ann Oncol 2018;29(4):888–94. https://doi.org/10.1093/annonc/mdy011.
[4] Miles D, von Minckwitz G, Seidman AD. Combination versus sequential single-agent therapy in metastatic breast cancer. Oncologist 2002;7(Suppl 6):13–5.
[5] de Mello Ramirez Medina J, de Araujo Trugilho I, Mendes GNB, Silva JG, da Silva Paiva MA, de Aguiar SS, Thuler LCS, Jannetti A. Advanced clinical stage breast disease: a cross-sectional study. Eur J Breast Health 2019;15(1):26–31. https://doi.org/10.1016/j.ejchb.2018.11.024.
[6] Kovic B, Guyatt G, Brundage M, Thabane L, Bhattacharjee N, Xie F. Association between progression-free survival and health-related quality of life in oncology: a systematic review protocol. BMJ Open 2016,6(9):e012095. https://doi.org/10.1136/bmjopen-2016-012095.
[7] Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, Andre F, Harbeck N, Aguilar Lopez B, Barrios CH, Bergh J, Biganzoli L, Boers-Doets CB, Cardoso M, Carey LA, Cortes J, Curigliano G, Dieras V, El Saghir NS, Eniu A, Fallowfield L, Francis PA, Gelmon K, Johnston S, Kaufman B, Koppikar S, Kroep IE, Mayer M, Nakagudde G, Oeffner BV, Onsho S, Pagani O, Paluch-Simon S, Penault-Llorca F, Prat A, Rusto HS, Sledge GW, Spence D, Thomssen C, Vorobiof DA, Xu B, Norton L, Winer EP. 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4). Ann Oncol 2018;29(2):1634–77. https://doi.org/10.1093/annonc/mdy192.
[8] Goetz MP, Johnston S, Martin M, Tokunaga E, Park RH, Huober J, et al. Health-related quality of life in MONARCH 3: abemaciclib plus an aromatase inhibitor as initial therapy in women with HR+, HER2– advanced breast cancer. In: SABCS annual meeting; 2018. Abstract P6-16-01.
[9] Verma S, O’Shaughnessy J, Burris HA, Campone M, Alba E, Chandiwana D, et al. Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2. Breast Cancer Res Treat 2018;170(3):535–45. https://doi.org/10.1007/s10549-018-4769-z.
[10] Turner NC, Huang Bartlett C, Cristofanilli M. Palbociclib in hormone-receptor-positive, advanced breast cancer: N Engl J Med 2015;373(17):1672–3. https:// doi.org/10.1056/NEJMc1510145.
[11] Gaulin C, Osorio G. Patient reported outcomes in metastatic breast cancer studies: evaluating the impact of the FDA guidance for industry. J Sci Innov Med 2019;2(1):4. https://doi.org/10.29024/jsim.39385.
[12] Krohe M, Hao Y, Lamoureaux RE, Galipeau N, Gloe D, Foley C, Mazar I, Solomon J, Sa L. Patient-reported outcomes in metastatic breast cancer: a review of industry-sponsored clinical trials. Breast Cancer Res Treat 2016;10:93–102. https://doi.org/10.4137/BCBCR.S39385.
[13] NCCN Clinical Practice Guidelines in Oncology. Breast Cancer; 2020. Version 2.2020.
[14] Hortobaggi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Petrakova K, Blackwell KL, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Monds L, Su F, Miller M, Elmeliegy M, Germa C, O’Shaughnessy J. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2–negative advanced breast cancer. Ann Oncol 2018;29(7):1541–7. https://doi.org/10.1093/annonc/mdy155.
[15] Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, Hurvitz SA, Chow L, Sohn J, Lee KS, Campos-Gomez S, Villanueva-Vazquez R, Jung KH, Babu KG, Wheatley-Price P, De Laurentis M, Im YH, Kuenmel S, El-Saghir N, Liu MC, Carlson G, Hughes G, Diaz-Padilla I, Germa C, Hirawat S, Lu YS. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol 2018;19(7):904–15. https://doi.org/10.1016/S1470-2045(18)30292-4.
[16] Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentis M, Im SA, Petrakova K, Bianchi DW, Esteva FJ, Martin M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Pivot X, Vidam G, Wang Y, Rodriguez-Lorenz K, Miller M, Taran T, Jerusalem G. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol 2018;36(24):2465–72. https://doi.org/10.1200/JCO.2018.78.9909.
[17] Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentis M, Im SA, Petrakova K, Val Bianchi D, Esteva FJ, Martin M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Pivot X, Sondhii M, Wang Y, Chakravarty A, Rodriguez-Lorenz K, Taran T, Jerusalem G. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med 2019;381(4):307–16. https://doi.org/10.1056/NEJMoa1903765.
[18] Breivik H, Cherry N, Collett B, de Conno F, Filbert P, Foubert AJ, Cohen R, Dow L. Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. Ann Oncol 2009;20(8):1420–33. https://doi.org/10.1093/annonc/mdp011.
[19] Scott NW, Fayers PM, Aaronson NK, Bottomley A, de Graeff A, Groenveld M, Gundy C, Moller K, Petersen MA, Sprangers MAG. EORTC QLQ-C30 reference values. 2008. Brussels, Belgium.
[20] Coltey S, Liegl P, Peterson MA, Aaronson NK, Costantini A, Fayers PM, et al. General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,385 persons across 13 European countries, Canada and the Unites States. Eur J Cancer 2019;107:153–63. https://doi.org/10.1016/j.ejca.2018.11.024.
[21] Cocks K, King MT, Velikova G, de Castro Jr G, Martin M, Kümmer M, Taylor D, Bardia A, Xu C, Chow L, Fanger KE, Hughes G, Miller M, Konek O, Chandiwana D, Colleoni M. Ribociclib plus tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2– advanced breast cancer: additional results from the MONALEESA-7 trial. In: European breast cancer conference (EBCC-11) 2018: abstract 79. https://doi.org/10.1007/s10549-018-4758-x.